Ethereum is trading at $1,936 after dropping below $2,000 for one of the most extended periods in recent memory, and the headlines make it look like the market Ethereum is trading at $1,936 after dropping below $2,000 for one of the most extended periods in recent memory, and the headlines make it look like the market

Ethereum Drops Below $2,000 as Harvard Rotates $86.8M Into ETH Trust and Whales Accumulate at Record Pace

2026/03/07 10:50
4 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

Ethereum is trading at $1,936 after dropping below $2,000 for one of the most extended periods in recent memory, and the headlines make it look like the market has given up on ETH entirely. But the data underneath those headlines tells a completely different story. Harvard’s $57 billion endowment just rotated $86.8 million from bitcoin ETFs into the iShares Ethereum Trust. Standard Chartered raised its year end ethereum target to $8,000. And as MarketWatchreported, institutional flows into ethereum products are accelerating even as the price sits near levels that most analysts consider deeply undervalued relative to the network’s fundamentals.

The ethereum story for 2026 is not over. The Glamsterdam upgrade is approaching on the development roadmap, analyst van de Poppe projects $10,000 to $17,500 in the next bullish expansion, and the network still processes 2.88 million transactions daily while hosting more than $50 billion in locked DeFi assets.

Ethereum Drops Below $2,000 as Harvard Rotates $86.8M Into ETH Trust and Whales Accumulate at Record Pace

But here is the part that ethereum holders need to evaluate honestly. Ethereum at $1,936 to $8,000 is approximately 4x. A strong return over time on a $240 billion asset. Not the multiplier that reshapes a financial outcome from the ground up.

Ethereum’s Infrastructure Problem Is Creating an Opportunity Ethereum Itself Cannot Offer

As Barron’s covered, ethereum’s gas fee extraction remains a persistent friction point. Transactions cost $5 to $50 depending on demand. Cross chain bridges charge $45 to $85. Research shows 49% of bridge users ended up with zero balance after gas consumed their remaining capital. That fee problem costs the ethereum ecosystem billions annually in lost trading value, and the project solving it at the infrastructure level just pulled $7.5 million at Fear Index 19 while ethereum holders debated whether $2,000 would hold.

The Founding Round Solving Ethereum’s Biggest Problem at Ethereum’s Worst Price

Pepeto is constructing the zero fee alternative to ethereum’s toll system. PepetoSwap eliminates gas entirely with zero cost execution across every major blockchain. The cross chain bridge consolidates fragmented ethereum liquidity into one audited interface. And the full exchange brings every digital asset under one roof, generating fee revenue from volume while users pay nothing per transaction.

SolidProof completed the audit. A former Binance executive joined the advisory board. Permanent revenue sharing distributes exchange fees to founding round wallets forever. A Web3 payment partnership accelerates the launch, confirmed at Fear Index 19. The original Pepe ecosystem cofounder who built a $2 billion asset leads everything. And 200% APY staking compounds daily.

The $7.5 million that entered during the worst ethereum sentiment in years did not arrive because of hype. It arrived because the wallets doing the work recognized that the project solving ethereum’s most expensive problem at founding round pricing offers a return profile that ethereum at $1,936 cannot structurally deliver.

Harvard Sees Ethereum’s Future. The Founding Round Captures It First.

Harvard is rotating in. Standard Chartered projects $8,000. Every institutional signal confirms ethereum’s cycle thesis is intact. But the returns from $1,936 to $8,000 unfold slowly across quarters while the founding round at Pepeto reprices at one listing event, and the 200% APY compounding daily in wallets that are not yours keeps widening the gap between those who entered during the fear and those who are still waiting for the ethereum chart to turn green.

Pepeto is going viral across every crypto outlet, the stages fill faster each round, and the entry available today vanishes permanently the moment the listing reprices the math. Visit the Pepeto official website and position before this stage fills completely and the price you see right now becomes a story other people tell.

Click To Visit Pepeto Website To Enter The Presale

FAQs

Is ethereum a good buy at $1,936?

Ethereum targets $8,000 per Standard Chartered with Harvard rotating $86.8 million into the ETH Trust. The 4x return is strong but Pepeto’s founding round offers higher multiples with 200% APY and permanent revenue sharing from exchange fees.

What is ethereum’s biggest problem in 2026?

Ethereum charges $5 to $50 per transaction in gas fees, costing traders billions annually. Pepeto eliminates those fees with zero cost execution while building exchange infrastructure that generates revenue from the volume ethereum’s fees currently extract. Visit the Pepeto official website.

What should ethereum holders buy for higher returns?

Pepeto with $7.5 million raised at Fear Index 19, zero fee execution solving ethereum’s gas problem, and 200% APY staking offers the multiplier that ethereum at $1,936 cannot structurally produce this cycle.

Comments
Market Opportunity
Ethereum Logo
Ethereum Price(ETH)
$1,987.02
$1,987.02$1,987.02
+0.44%
USD
Ethereum (ETH) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09